Table 1.
Baseline characteristics of incident ADD users (inception cohort)
| Sulfonylurea (SU) † only users | Metformin only users | |||
|---|---|---|---|---|
| Characteristics | n = 32 438 | (%) | n = 132 960 | (%) |
| Follow‐up time (years) | ||||
| Mean (SD) | 7.6 | (5.2) | 5.3 | (3.7) |
| Median (IQR) | 7.0 | (3.0–11.6) | 4.6 | (2.2–7.7) |
| Sex | ||||
| Female | 13 817 | (42.6) | 63 709 | (47.9) |
| Male | 18 621 | (57.4) | 69 251 | (52.1) |
| Age at index date (years) | ||||
| Mean (SD) | 66.0 | (13.2) | 58.3 | (14.8) |
| Median | 67 | 60 | ||
| By category | ||||
| 18–29 | 157 | (0.5) | 5756 | (4.3) |
| 30–39 | 849 | (2.6) | 9825 | (7.4) |
| 40–49 | 2828 | (8.7) | 18 976 | (14.3) |
| 50–59 | 5920 | (18.3) | 31 562 | (23.7) |
| 60–69 | 8777 | (27.1) | 34 996 | (26.3) |
| 70–79 | 8900 | (27.4) | 23 745 | (17.9) |
| 80+ | 5007 | (15.4) | 8100 | (6.1) |
| Smoking status | ||||
| Never smoker | 16 615 | (51.2) | 63 371 | (47.7) |
| Current smoker | 6248 | (19.3) | 25 146 | (18.9) |
| Former smoker | 9575 | (29.5) | 44 443 | (33.4) |
| Body mass index (kg m−2) | ||||
| <20 | 1054 | (3.2) | 921 | (0.7) |
| 20–24.9 | 8768 | (27.0) | 11 197 | (8.4) |
| 25–39.9 | 12 718 | (39.2) | 39 402 | (29.6) |
| > = 30 | 8512 | (26.2) | 79 758 | (60.0) |
| Unknown | 1386 | (4.3) | 1682 | (1.3) |
| HbA1c on index date (mean (SD)) | 9.2 | (2.1) | 8.5 | (1.8) |
| History of complications | ||||
| Neuropathy | 829 | (2.6) | 4574 | (3.4) |
| Retinopathy | 953 | (2.9) | 4551 | (3.4) |
Incident, all index patients are included after 1 year lead‐in time without anti‐diabetic drugs (ADD) prescription; IQR, interquartile range; SD, standard deviation.
†
Glibenclamide, gliclazide, glimepiride, glipizide, gliquidon.
Due to the large sample sizes, all analyses of baseline characteristics are statistically significant.